Ahlemann L M, Staab H J, Koch H L, Anderer F A
Oncodev Biol Med. 1980;1(3):143-50.
Serial CEA measurements performed in 102 lung cancer patients during and after radiotherapy and chemotherapy correlated well with the course of disease. CEA levels above 10 ng CEA/ml prior to radiotherapy signaled metastatic spread even when this was not evident from clinical staging of the patient (TNM). This finding contributed to the early adoption of radiotherapy in favor of palliative treatment. Alterations of the CEA concentration during therapy could be used for monitoring the efficiency of treatment. Increasing CEA levels always signaled disease progression, decreasing CEA levels were found to be associated with improvement. In the posttreatment follow-up, increasing CEA levels were always reliable predictors of recurrent disease. Slope analysis of the posttreatment CEA time courses discriminated bone and/or liver metastases with a slope greater than 0.5 ng/ml/10 days from local recurrences, lymph node, lung and brain metastases with slope values less than 0.5 ng/ml/10 days.
在102例肺癌患者放疗和化疗期间及之后进行的连续癌胚抗原（CEA）测量结果与疾病进程密切相关。放疗前癌胚抗原水平高于10 ng CEA/ml，即使从患者的临床分期（TNM）中未明显看出，也提示有转移扩散。这一发现促使早期采用放疗以利于姑息治疗。治疗期间癌胚抗原浓度的变化可用于监测治疗效果。癌胚抗原水平升高总是提示疾病进展，而癌胚抗原水平降低则与病情改善相关。在治疗后的随访中，癌胚抗原水平升高始终是疾病复发的可靠预测指标。治疗后癌胚抗原时间进程的斜率分析可区分斜率大于0.5 ng/ml/10天的骨和/或肝转移与斜率值小于0.5 ng/ml/10天的局部复发、淋巴结、肺和脑转移。
